# China-Administration of Nicorandil Group（CHANGE）

Study · id `cardio:ct-nct03445728` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03445728](<https://clinicaltrials.gov/study/NCT03445728>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03445728

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 238 participants.

## Technical summary

Registry record NCT03445728. Randomized; quadruple masking; primary purpose treatment. Start 2018-02-24 (actual); primary completion 2020-07-31 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 238 participants (enrolled count; ClinicalTrials.gov record NCT03445728, source copy `cardio:ctgov-nct03445728-2021-11-24`, retrieved 2026-10-26)
- Started: 2018-02-24 (actual) (ClinicalTrials.gov record NCT03445728, source copy `cardio:ctgov-nct03445728-2021-11-24`, retrieved 2026-10-26)
- Primary completion: 2020-07-31 (actual) (ClinicalTrials.gov record NCT03445728, source copy `cardio:ctgov-nct03445728-2021-11-24`, retrieved 2026-10-26)
- Completion: 2021-10-01 (actual) (ClinicalTrials.gov record NCT03445728, source copy `cardio:ctgov-nct03445728-2021-11-24`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT03445728, source copy `cardio:ctgov-nct03445728-2021-11-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03445728-2021-11-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: China-Administration of Nicorandil Group（CHANGE）
- Condition: Myocardial Infarction
- Condition: Percutaneous Coronary Intervention
- Condition: Nicorandil
- Intervention (Drug): Nicorandil
- Intervention (Other): Placebo
- Lead sponsor: Chinese PLA General Hospital
- Lead sponsor class: OTHER
- Collaborator: First People's Hospital of Yulin
- Collaborator class: OTHER
- Collaborator: Beijing Chao Yang Hospital
- Collaborator class: OTHER
- Collaborator: Wuhan Asia Heart Hospital
- Collaborator class: OTHER
- Collaborator: Hainan General Hospital
- Collaborator class: OTHER
- Collaborator: Zunyi Medical College
- Collaborator class: OTHER
- Collaborator: Guizhou Provincial People's Hospital
- Collaborator class: OTHER
- Collaborator: Second Affiliated Hospital of Nanchang University
- Collaborator class: OTHER
- Collaborator: The Second Hospital of Hebei Medical University
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry lists this organization as the lead sponsor: Chinese PLA General Hospital (`cardio:org-chinese-pla-general-hospital`)
- Registry lists this organization as a collaborator: First People's Hospital of Yulin (`cardio:org-first-people-s-hospital-of-yulin`)
- Registry lists this organization as a collaborator: Beijing Chao Yang Hospital (`cardio:org-beijing-chao-yang-hospital`)
- Registry lists this organization as a collaborator: Wuhan Asia Heart Hospital (`cardio:org-wuhan-asia-heart-hospital`)
- Registry lists this organization as a collaborator: Zunyi Medical College (`cardio:org-zunyi-medical-college`)
- Registry lists this organization as a collaborator: Guizhou Provincial People's Hospital (`cardio:org-guizhou-provincial-people-s-hospital`)
- Registry lists this organization as a collaborator: Second Affiliated Hospital of Nanchang University (`cardio:org-second-affiliated-hospital-of-nanchang-university`)
- Registry lists this organization as a collaborator: The Second Hospital of Hebei Medical University (`cardio:org-the-second-hospital-of-hebei-medical-university`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effects of Nicorandil Administration on Infarct Size in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: The CHANGE Trial (`cardio:pubmed-36073634`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: cd40c242fb2e09b9ac27aba10e44f60f4574b0f19c21b07031e2ca17fd46b3ba
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
